中新网7月12日电 据食药监局网站消息，国家食品药品监督管理局密切关注发生在美国的罗氏公司瞒报事件进展情况，从目前情况看，该事件涉及药品在中国不良反应监测中尚未发现异常报告。

Beijing July 12-according to the administration's food web news，The state food and drug administration pay close attention to happens in America's botched blood-collection drive roche's progress，From what we see，The incident involving drug adverse reaction monitoring in China has not been found abnormality report。

　　据悉，国家食品药品监督管理局约谈了罗氏(中国)公司安全官，责成罗氏(中国)公司报告该事件的评价结果；并向世界卫生组织和英国、美国药监机构了解有关情况，希望及时通报该事件的调查结果。同时加强对罗氏公司在中国销售的相关品种的不良反应监测。

It is reported，The state food and drug administration interviewed the roche(China)The company safety officer，Instruct the roche(China)The results of the evaluation of the incident report；And to the world health organization and the UK、The United States about the drug watchdogs，Hope this incident promptly inform the survey results。At the same time, strengthen roche to sell in China related kind of adverse reaction monitoring。